The methylation industry is transforming, but legacy methods like microarrays and bisulfite sequencing still lack the sensitivity for clinical integration, hindering biomarker discovery and clinical impact. Wasatch BioLabs’ Direct Whole Methylome Sequencing (dWMS) delivers a comprehensive solution, offering whole genome sequencing and methylation analysis with unmatched quality and flexibility.
Designed to meet the needs of research and biomarker discovery, dWMS delivers scalable multi-omic solutions to advance assay development, epigenetic studies, and beyond.
Traditional methylation technologies leave researchers guessing—are regions uniformly 10% methylated, or is methylation concentrated in just 10% of the region?
Wasatch BioLabs’ dWMS service resolves this uncertainty. By analyzing over 96% of CpGs across the genome, dWMS captures the full methylation context across entire DNA molecules with native reads, enabling precise, molecule-level analyses.
Capturing 30X more CpG sites and 2X more CpG islands without bisulfite or amplification biases, researchers gain a comprehensive view of methylation, hydroxymethylation, and DNA sequence—all in a single run.
dWMS identifies 2.4x more differentially methylated CpG islands (CGIs) than traditional microarrays. gDNA was extracted from Tissue 1 (n=4) and Tissue 2 (n=4) and analyzed with both methylation array and dWMS. dWMS captured 2.4 times more CGIs containing significant differential methylation between the two tissues, including 91% of those detected by the array.
WBL’s dWMS demonstrates robust reproducibility with minimal inter-sample variance. DNA samples from Tissue 1 (n=4) and Tissue 2 (n=4) underwent sequencing on two separate PromethION platforms at distinct sites. Correlation analysis (A) and PCA visualization (B) reveal high concordance within both Tissue 1 and Tissue 2 cohorts (r > 0.97), underscoring negligible variation attributable to site-specific batch effects.
Leveraging nanopore sequencing, dWMS long reads resolve repetitive regions, structural variants, phasing, and other complex genomic features. This capability enhances genome assemblies, reveals complex regulatory elements, and provides deeper insights into genomic architecture.
Liquid biopsies are transforming precision medicine by providing non-invasive insights into health and disease. Wasatch BioLabs’ Direct Methylation Sequencing (dMS) for cfDNA addresses traditional methods limitations with optimized protocols and native nanopore sequencing, delivering precision, data with unmatched resolution and reliability.
To support genome assembly studies, Wasatch BioLabs offers three scalable solutions that deliver assembled genome DNA sequence and methylation data: moderate-coverage draft genomes for gene discovery, ultra-long-read chromosome-level assemblies for resolving complex regions, and advanced assemblies integrating RNA sequencing for functional insights. These unbiased, high-quality de novo assemblies accommodate any species and genome length, leveraging long reads to resolve complex regions with precision.
Wasatch BioLabs introduces MethylSeqR, a user-friendly R package that simplifies the transition from methylation arrays to dWMS. MethylSeqR utilizes proprietary .CH3 files, which compress data by up to 95%, streamlining both analysis and storage.
Seamlessly integrating with familiar pipelines, MethylSeqR makes advanced methylation analysis accessible to both newcomers and experienced users of nanopore sequencing, accelerating research and clinical applications.
Perform genome-wide methylation analyses in record time.
Analyses in just three steps: Import Data, Run QC, and Analyze.
Compress 20 GB outputs to 1 GB, optimizing storage and transfer.
Process large-scale tasks seamlessly with on-disk database support.
(A) Positional Summary
(B) Summaries By Region
(C) Heat Map
(D) Volcano Plot
